Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CTA101 in Relapsed or Refractory CD19+ B-cell Acute Lymphoblastic Leukemia
NCT04154709Phase 1Unknown
- Start
- Dec 2019
- Primary completion
- Nov 2021
- Modality
- Gene Silencing, CRISPR-Cas9, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CTA101 in acute lymphoblastic leukemia (ALL). Primary endpoint: Dose-limiting toxicity at 28 days. Status: unknown.
02
Drugs
CTA101
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT04154709.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04154709.